摘要
目的:对比唑来膦酸及云克治疗骨质疏松症的疗效及机制。方法:2011年7月到2015年11月选择在海南医学院第一附属医院诊治的原发性骨质疏松症患者患者232例,根据治疗药物的不同分为云克组116例与唑来膦酸组116例,唑来膦酸组给予唑来膦酸治疗,1年1次。云克组给予云克治疗,治疗10 d为1个疗程,每3个月1个疗程,共连续观察3年,记录两组预后疗效与骨密度、血液学指标变化情况。结果:唑来膦酸组与云克组的总有效率分别为99.1%和90.0%,唑来膦酸组高于云克组(P<0.05)。两组治疗后的腰椎与髋部骨密度显著高于治疗前,唑来膦酸组高于云克组(P<0.05)。两组治疗后的关节压痛评分均明显低于治疗前,云克组明显低于唑来膦酸组(P<0.05)。两组治疗后的血钙、血磷含量在组内与组间对比差异都无统计学意义(P>0.05),红细胞沉降率(erythroeyte sedimentation rate,ESR)含量都低于治疗前(P<0.05),治疗后云克组ESR含量也显著低于唑来膦酸组(P<0.05)。结论:唑来膦酸和云克在骨质疏松症治疗中的应用能提高骨密度,缓解关节压痛症状,降低ESR含量。但唑来膦酸提高骨密度比云克显著,云克缓解关节疼痛比唑来膦酸显著,且不会影响患者的血钙、血磷含量。
Objective:To compare the efficacy and mechanism of zoledronic acid and Tc-MDP in the treatment of osteoporosis.Methods:A total of 232 patients with primary osteoporosis and treated in the First Affiliated Hospital of Hainan Medical College from July 2011 to November 2015 were selected and were divided into the Tc-MDP group and zoledronic acid group accorded with 116 cases each to the respective treatment ways.The zoledronic acid group was given zoledronic acid treatment,1 time per year.The Tc-MDP group was given Tc-MDP treatment,and the treatment were treated for 10 days for 1 course,1 course for 3 months,and a total of 3 years of treatment were observed.The prognosis and the changes of bone mineral density and hematological parameters were recorded.Results:The total effective rates of the zoledronic acid group and Tc-MDP group were 99.1%and 90.0%,respectively,and the zoledronic acid group was significantly higher than the Tc-MDP group(P<0.05).The bone mineral density of lumbar vertebrae and hip after treatment were significantly higher than that of the two groups before treatment,and the zoledronic acid group were also significantly higher than the Tc-MDP group(P<0.05).The joint tenderness scores of the two groups were significantly lower than those before treatment,and the score of Tc-MDP group was also significantly lower than that of zoledronic acid group(P<0.05).There were no significant differences in serum calcium and blood phosphorus levels compared between the two groups(P>0.05),and the erythroeyte sedimentation rate(ESR)levels were lower than before treatment(P<0.05),The ESR levels of the Tc-MDP group were also significantly lower than that of the zoledronic acid group(P<0.05).Conclusion:The zoledronic acid and the application of Tc-MDP in the treatment of osteoporosis can increase bone density,relieve joint tenderness symptoms,reduce ESR content,and will not affect patients'blood calcium and blood phosphorus levels.However,zoledronic acid increases bone density significantly are better than the Yunke,and Yunke relieves joint pain significantly are more than zoledronic acid.
作者
周影
潘卫民
孙雯
王超群
严娟娟
谢权
黄莹
肖欢
颜卫文
ZHOU Ying;PAN Wei-Min;SUN Wen;WANG Chao-Qun;YAN Juan-Juan;XIE Quan;HUANG Ying;XIAO Huan;YAN Wei-Wen(Department of Nuclear Medicine, The First Affiliated Hospital of Hainan Medical University, Haikou 570102,China;Department of Nuclear Medicine, Hainan General Hospital, Haikou 570102,China)
出处
《海南医学院学报》
CAS
2020年第16期1237-1241,1249,共6页
Journal of Hainan Medical University
基金
海南省自然科学基金项目(811213)。
关键词
唑来膦酸
云克
骨质疏松症
红细胞沉降率
骨密度
Zoledronic acid
Tc-MDP
Osteoporosis
Erythrocyte sedimentation rate
Bone density
